Clinical Trial Update: Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating cyclosporine 0.1% combined with loteprednol 0.2% for normalization of the anterior segment in dry eye patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye

Drugs mentioned

• Cyclosporine 0.1% (cyclosporine)
• Loteprednol 0.2% (loteprednol)

Snippet

Sponsor: Research Insight LLC | Conditions: Dry Eye | Phase 3 | Status: COMPLETED